Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins

Area of Science:

• Biochemistry
• Molecular Biology
• Nanotechnology

Background:

• Cancer cells exhibit specific receptor expression, offering targets for drug delivery.
• Existing cancer therapies can be limited by efficacy and side effects.
• Developing targeted protein therapeutics requires integrating multiple scientific disciplines.

Purpose of the Study:

• To engineer synthetic multidomain protein therapeutics for selective cancer cell sensitization.
• To enhance the antitumor efficacy of existing chemotherapeutics.
• To create novel multiprotein complexes using supramolecular chemistry and protein engineering.

Main Methods:

• Assembling multiprotein complexes via supramolecular interactions at the nanoscale.
• Utilizing chemically modified somatostatin for targeting SST-2 receptors on A549 lung cancer cells.
• Incorporating a novel cysteine mutant of the C3bot1 (C3) enzyme as a Rho protein inhibitor.

Main Results:

• The engineered complex, SST3-Avi-C3, successfully retargeted the C3 enzyme into non-small cell lung A549 cancer cells.
• SST3-Avi-C3 demonstrated exceptional tumor inhibition in vivo, at concentrations significantly lower than bevacizumab.
• The complex enhanced tumor sensitivity to conventional chemotherapeutics like doxorubicin.

Conclusions:

• The integrated approach of supramolecular chemistry, protein chemistry, and molecular biology is effective for engineering targeted cancer therapeutics.
• SST3-Avi-C3 shows potential as a novel agent for targeted and combination cancer therapy.
• This strategy expands the possibilities for developing advanced multidomain protein complexes for oncology.